# Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

> **NCT07192900** · PHASE1 · RECRUITING · sponsor: **David Bartlett, MD** · enrollment: 10 (estimated)

## Conditions studied

- Malignant Pleural Effusion
- Malignant Mesothelioma
- Pleural Effusion, Malignant
- Metastasis to Pleura

## Interventions

- **BIOLOGICAL:** locally manufactured adoptive cellular therapy (ACT) product
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT07192900
- **Lead sponsor:** David Bartlett, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2032-12
- **Final completion:** 2037-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07192900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07192900, "Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT07192900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*